ClinicalTrials.gg
Active, not recruitingNCT06411249Updated Oct 27, 2026

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

A Phase 4 interventional study of Belimumab (GSK1550188) in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Active, not recruiting at 104 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Updated Oct 27, 2026Study completion movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
302
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
10th of 36
302 · median 81
Started
2024
with 2 others
Phase 4
10 of 36
2 open now
Registered
33rd of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 10th largest by enrollment, is one of 3 that started in 2024, is one of 10 in phase 4, and was the 33rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Belimumab
  • Benlysta
  • Efficacy
  • Safety
  • Early Use
  • Systemic Lupus Erythematosus
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of systemic lupus erythematosus (SLE) within 2 years of signing the according to the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria 2019
  • Have unequivocally positive autoantibody test results defined as an Anti-nuclear antibody (ANA) titer greater than or equal to (>=) 1:80 and/or a positive anti-Double stranded deoxyribonucleic acid (dsDNA) serum antibody test from 2 independent time points
  • Active SLE defined as:
  • Clinical SLEDAI-2K (excluding anti-dsDNA and C3/C4) score greater than (>) 4, OR
  • Clinical SLEDAI-2K (excluding anti-dsDNA and C3/C4) score 1 to 4 and prednisone or equivalent dose >=10 milligram per day (mg/day)
  • The Systematic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) = 0 at Screening
  • Male and/or female; a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • Not a Woman of (WOCBP) OR
  • Is a WOCBP and using a method that is highly effective
  • Capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal (GI), hepatic, renal, neurological, psychiatric, malignancy, or infectious diseases) and/or a planned surgical procedure, which, in the opinion of the principal investigator (PI), could confound the results of the clinical study or put the participant at undue risk.
  • Participants with history of major organ transplant or hematopoietic stem cell/marrow transplant or renal transplant.
  • Have an acute or chronic infection including requiring management as follows:
  • Currently on any suppressive therapy for a chronic infection such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria.
  • A serious infection requiring treatment with intravenous or Intramuscular (IV/IM) antibiotics and/or hospitalization if the last dose of antibiotics or the hospital discharge date was within 60 days of the first day of dosing (Day 1). Prophylactic anti-infective treatment is allowed.
  • Confirmed active or untreated latent tuberculosis (TB):
  • Diagnosis of active TB confirmed by: 1) evidence of active TB disease from chest imaging (posterior anterior and lateral x-rays or chest computed tomography [CT]), 2) medical history and physical examination, and 3) either positive microscopy smear/culture for mycobacteria or positive TB polymerase chain reaction (PCR), i.e., Xpert. A tuberculin skin test (TST) or an interferon gamma release assay (IGRA) will be done for all participants. A positive TST or a positive (not indeterminate) IGRA TB test such as QuantiFERON-TB Gold Plus test is indicative but not required for diagnosis of active TB. A positive TST is defined as a skin induration >=5 millimeter (mm) at 48 to 72 hours (regardless of Bacillus Calmette-Guerin or other vaccination history).
  • Untreated latent tuberculosis infection (LTBI) confirmed by: 1) no evidence of active TB based on chest imaging, medical history and physical examination and laboratory evaluation of sputum; and 2) a positive TST, defined as a skin induration >5 mm at 48 to 72 hours, regardless of Bacillus Calmette-Guerin or other vaccination history); or a positive (not indeterminate) IGRA TB test such as QuantiFERON-TB Gold Plus test. Those with IGRA positive tests or positive TST who can document ongoing LTBI treatment for at least 4 weeks may be enrolled. Those with IGRA positive tests with documentation of the following may also be enrolled:
  • Successful completion of treatment for active TB.
  • Completion of treatment for LTBI (with treatment as per local practice, for example: 3 months of isoniazid and rifampin or 4 months of rifampin or 3 months weekly isoniazid and rifapentine, or 9 months of isoniazid).
  • Confirmed Progressive multifocal leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms.
  • Have severe active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, Cerebrovascular accident (CVA), cerebritis, or CNS vasculitis) requiring therapeutic intervention within 60 days of Screening.
  • Active Lupus Nephritis defined as active urinary sediment and/or proteinuria >500 milligrams (mg) per 24 hours, or equivalent using spot urine protein to creatinine ratio, requiring induction therapy not permitted by protocol.
  • Participants with patient health questionnaire (PHQ)-9 score >=10 that in the opinion of a mental healthcare professional pose a serious suicide risk, or any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk. NOTE: For participants with a PHQ-9 score >=10, at the Screening visit or at the day 1 visit before the first administration of the study drug, it is required that they be referred for an assessment by a mental healthcare professional (e.g., locally licensed psychiatrist, psychologist, or master's level therapist) before the investigator makes a final decision regarding suitability for enrollment.
  • Known to have titers of human anti-mouse antibody or history of reactions when treated with diagnostic or therapeutic monoclonal antibodies
  • Live or (s) within 35 days prior to Screening or plans to receive such vaccines during the Screening period or during the clinical study
  • Chronic oral use for a non-SLE disorder at the Screening study visit (e.g., for asthma). Inhaled steroid use will be allowed.
  • Treatment at or prior to Screening study visit:
  • Treatment at Screening study visit with any of the following:
  • Azathioprine (AZA) >200 mg/day
  • Methotrexate (MTX) (any formulation) >25 mg/week
  • Mycophenolate mofetil (MMF) (oral [PO])/MMF hydrochloride (IV) >2 grams (g)/day
  • Mycophenolate acid/sodium (PO) >1.44 g/day
  • Oral cyclophosphamide >2.5 mg/kilograms (kg)/day
  • Tacrolimus >0.2 mg/kg/day
  • Cyclosporine (PO) >2.5 mg/kg/day
  • Treatment within specified timeframe prior to Screening:
  • Intra-articular, IM, or IV corticosteroids within 6 weeks of Day 1
  • Daily use of >1 Nonsteroidal anti-inflammatory (NSAID) within 2 weeks prior to Day 1
  • Treatment at any time prior to Screening with any of the following:
  • use of conventional (ISs) or anti-malarials (AMs)
  • Commercially available Belimumab (BEL)
  • Anifrolumab
  • Rituximab or other B cell depleting therapies
  • Anti-tumor necrosis factor (TNF) therapy (e.g., adalimumab, etanercept, infliximab)
  • Other treatments with effects on the immune system (e.g., abatacept, interleukin-1 receptor antagonist [anakinra], Janus kinase (JAK) inhibitors)
  • IV cyclophosphamide
  • IV immunoglobulin
  • Plasmapheresis Any addition of a new IS or AM, or IS or AM switch, performed more than 3 months after initiating first line therapy in response to inadequate disease control is considered second-line therapy and is therefore exclusionary. Therapy changes made due to intolerance or toxicity are not considered second-line, provided that the intolerance/toxicity is clearly documented. Any therapy changes after initiating first line therapy considered to be due to intolerance/toxicity must be reviewed and confirmed by the EAC prior to determining eligibility.
  • History of primary immunodeficiency, or hypogammaglobulinemia (Immunoglobulin G [IgG] \<400 mg/deciliter [dL]) or Immunoglobulin A (IgA) deficiency (IgA \<10 mg/dL) at Screening
  • Have a Grade 3 or greater neutropenia, defined as \<1000/cubic millimeter (mm3) (\<1.0 x10\^9/liter [L]) based on the (CTCAE) version (v) 5.0
  • >2 x (ULN)
  • Total >1.5 x ULN; For participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN if direct bilirubin is ≤1.5xULN. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome), asymptomatic gallstones, and chronic stable (in whom Hepatitis D [HDV] has been excluded) or C are acceptable if participant otherwise meets entry criteria.
  • Have any other abnormal laboratory value, that in the opinion of the investigator, is capable of significantly altering the absorption, metabolism, or elimination of the clinical study intervention; or constitutes a risk when taking the clinical study intervention or interferes with the interpretation of the clinical study data.
  • Positive (HIV) antibody test
  • Serologic evidence of Hepatitis B (HB) infection based on the results of testing for hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc) and anti-HBs will be excluded as follows:
  • Participants positive for HBsAg.
  • Participants negative for HBsAg but positive for Anti-HBc and detectable hepatitis B virus (HBV) DNA, regardless of Anti-HBs antibody status.
  • Positive antibody test result at Screening or within 3 months prior to starting study intervention. NOTE: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C Ribonucleic acid (RNA) test is obtained.
  • Positive Hepatitis C RNA test result at Screening or within 3 months prior to first dose of study intervention. NOTE: Test is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.
  • Sensitivity to the clinical study intervention, or components thereof, or monoclonal antibodies or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the clinical study
  • Current drug or alcohol dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 1
  • Current enrolment or past participation in any other clinical study involving an study intervention (including investigational vaccines) within 3 months or 5 half-lives of the investigational drug (whichever is longer) before enrolment
  • Unable to administer clinical study intervention by subcutaneous (SC) auto-injector at home and has no other reliable resource to administer the study intervention at home.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Belimumab (GSK1550188)

    Participants will receive GSK1550188.

    Biological: Belimumab (GSK1550188)

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52

    LLDAS is defined as Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) less than or equal to (\<=) 4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no new features of lupus disease activity compared with the previous assessment, Physician Global Assessment (PGA) \<= 1, with a 7-day average oral prednisone equivalent dose for SLE reasons \<= 7.5 milligram (mg)/day and stable treatment and without discontinuing due to lack of efficacy, dying, or taking prohibited medications.

    Time frame: At Week 52

Secondary outcomes

  1. Part A: Percentage of Participants Achieving SLE Responder Index 4 (SRI4) at Week 52

    SRI4 is defined as greater than or equal to (\>=) 4-point reduction from baseline in SLEDAI-2K score and no worsening (increase of less than \[\<\] 0.30 points from baseline) in PGA and no new Easy- British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new Easy-BILAG B organ domain scores compared with baseline at the time of assessment without participants discontinuing due to lack of efficacy, dying, taking prohibited medications or meeting treatment failure criteria.

    Time frame: At Week 52

  2. Part A: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) for >= 25 percent (%) of time from Day 1 to Week 52

    LLDAS is defined as Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) less than or equal to (\<=) 4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no new features of lupus disease activity compared with the previous assessment, Physician Global Assessment (PGA) \<= 1, with a 7-day average oral prednisone equivalent dose for SLE reasons \<=7.5 milligram (mg)/day and stable treatment and without discontinuing due to lack of efficacy, dying, or taking prohibited medications.

    Time frame: Day 1 and up to Week 52

  3. Part A: Percentage of Participants Achieving Average Oral Prednisone Equivalent Dose <= 5 mg/day at Week 52

    A seven-day average oral prednisone equivalent dose \<= 5 mg/day at week 52, if oral prednisone equivalent dose is greater than (\>) 5 mg/day at baseline without study intervention discontinuation due to lack of efficacy, serious AE, prohibited medication intake, or treatment failure by Week 52.

    Time frame: At Week 52

  4. Part A: Estimate of probability of having a Severe Flare defined as modified SELENA-SLEDAI Flare Index (SFI) at Week 52

    SFI Flare was defined as a mild/moderate or severe flare according to the modified Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) SLE Flare Index (modified excluded severe flares from the SELENA-SLEDAI flare assessment that were triggered only by an increase in SLEDAI-2K score to \>12). Change in SELENA SLEDAI instrument score of greater than 12.

    Time frame: At Week 52

  5. Part A: Percentage of Participants Achieving a >= 50% Improvement in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score at Week 52

    The CLASI is used to assess the cutaneous lesions of SLE and consists of 2 separate scores: the activity score and the damage score. The activity score evaluates erythema, scale/hypertrophy, mucous membrane lesions, recent hair loss, and nonscarring alopecia, measured at 13 anatomical sites on the skin. The total activity score ranges from 0 to 70. Higher scores indicate greater disease activity and severity in SLE.

    Time frame: At Week 52

  6. Part A: Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue at Week 52

    The FACIT-Fatigue is a 13-item participant-completed questionnaire used to assess the impact of fatigue over the previous 7 days. Item responses range from 0 (Not at All) to 4 (Very Much). The FACIT-Fatigue is scored as the sum of item responses, with range from 0 to 52, where higher scores indicate less fatigue and a better quality of life.

    Time frame: Baseline (Day 1) and at Week 52

  7. Part A: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs of Special Interest (AESIs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a participant's offspring; abnormal pregnancy outcomes; is a suspected transmission of any infectious agent via an authorized medicinal product; or other situations as per the Investigator's medical or scientific judgment. AESIs will include hypersensitivity or post-injection systemic reactions, infections of special interest, malignancy, psychiatric events, and fatal events.

    Time frame: Up to Week 52

  8. Part B: Percentage of Participants Achieving Definition of Remission in SLE (DORIS) Remission at Week 104

    DORIS remission is defined as clinical SLEDAI-2K equal to (=) 0 (excluding anti- double stranded deoxyribonucleic acid \[dsDNA\] and complement); and PGA \< 0.5; and prednisone (or equivalent dose) \< 5 mg/day on stable anti-malarial (AM), immunosuppressants (ISs) and biologic therapy.

    Time frame: At Week 104

  9. Part B: Percentage of Participants Maintaining Systematic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) of 0

    The SDI measures irreversible changes occurring since the diagnosis of SLE. The questionnaire contains 39 items covering 12 different organ systems. Individual ranges for organ systems are ocular: 0-2, neuropsychiatric: 0-6; renal: 0-3; pulmonary: 0-5; cardiovascular: 0-6; peripheral vascular: 0-5; gastrointestinal: 0-5; musculoskeletal: 0-6; skin: 0-3; endocrine (diabetes): 0-1; gonadal: 0-1; and malignancies: 0-2. The SDI score is calculated by summing the individual scores for 12 organ systems and ranges from 0 (no damage) to 45 (increasing disease damage) where higher score indicates increasing disease damage severity.

    Time frame: Up to Week 156

  10. Part B: Number of Participants With AEs, SAEs, and AESIs up to Week 104 and Week 156

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in a participant's offspring; abnormal pregnancy outcomes; is a suspected transmission of any infectious agent via an authorized medicinal product; or other situations as per the Investigator's medical or scientific judgment. AESIs will include hypersensitivity or post-injection systemic reactions, infections of special interest, malignancy, psychiatric events, and fatal events.

    Time frame: Up to Week 104 and Week 156

07

Study locations

104 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Flagstaff, Arizona 86001, United States
  • GSK Investigational Site
    Mesa, Arizona 85210, United States
  • GSK Investigational Site
    Tucson, Arizona 85748, United States
  • GSK Investigational Site
    Covina, California 91722, United States
  • GSK Investigational Site
    Fontana, California 92335, United States
  • GSK Investigational Site
    Fullerton, California 92835-3827, United States
  • GSK Investigational Site
    Long Beach, California 90720, United States
  • GSK Investigational Site
    Los Angeles, California 90211, United States
  • GSK Investigational Site
    Mission Hills, California 91345-1116, United States
  • GSK Investigational Site
    San Diego, California 92128, United States
  • GSK Investigational Site
    Temecula, California 92592, United States
  • GSK Investigational Site
    Tujunga, California 91042-2706, United States
  • GSK Investigational Site
    Van Nuys, California 92307-2333, United States
  • GSK Investigational Site
    Van Nuys, California 92586, United States
  • GSK Investigational Site
    Whittier, California 90602, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Clearwater, Florida 33765-2616, United States
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
  • GSK Investigational Site
    Tampa, Florida 33606, United States
  • GSK Investigational Site
    Atlanta, Georgia 30152, United States
  • GSK Investigational Site
    Morton Grove, Illinois 60521, United States
  • GSK Investigational Site
    Rockford, Illinois 60123, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70836, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Lansing, Michigan 48910, United States
  • GSK Investigational Site
    Brooklyn, New York 11201, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28202, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • GSK Investigational Site
    Duncansville, Pennsylvania 16635-8445, United States
  • GSK Investigational Site
    Austin, Texas 78745, United States
  • GSK Investigational Site
    Baytown, Texas 77521, United States
  • GSK Investigational Site
    Colleyville, Texas 76034-5913, United States
  • GSK Investigational Site
    Fort Worth, Texas 76109-3559, United States
  • GSK Investigational Site
    Houston, Texas 77089, United States
  • GSK Investigational Site
    Katy, Texas 77494-1341, United States
  • GSK Investigational Site
    Plano, Texas 75024, United States
  • GSK Investigational Site
    Danville, Virginia 24541, United States
  • GSK Investigational Site
    Glendale, Wisconsin 53217, United States
  • GSK Investigational Site
    Berazategui, 1884, Argentina
  • GSK Investigational Site
    Buenos Aires, C1121ABE, Argentina
  • GSK Investigational Site
    Buenos Aires, C1406AGA, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, 1425, Argentina
  • GSK Investigational Site
    La Plata, B1900AX, Argentina
  • GSK Investigational Site
    Mar del Plata, 7600, Argentina
  • GSK Investigational Site
    Quilmes, B1878GEG, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, CP 4000, Argentina
  • GSK Investigational Site
    Santa Fe, S2000DSV, Argentina
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-221., Brazil
  • GSK Investigational Site
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • GSK Investigational Site
    Cuiabá, 78020-840, Brazil
  • GSK Investigational Site
    Juiz de Fora, 36010-570, Brazil
  • GSK Investigational Site
    Passo Fundo, 99010-080, Brazil
  • GSK Investigational Site
    Porto Alegre, 90035-001, Brazil
  • GSK Investigational Site
    Porto Alegre, 90430-001, Brazil
  • GSK Investigational Site
    Porto Alegre, 90610-000, Brazil
  • GSK Investigational Site
    Salvador, 41820-020, Brazil
  • GSK Investigational Site
    São Paulo, 01323-001, Brazil
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
  • GSK Investigational Site
    Angers, 49933, France
  • GSK Investigational Site
    Saint-Priest-en-Jarez, 42270, France
  • GSK Investigational Site
    Toulouse, 31400, France
  • GSK Investigational Site
    Mainz, Rhineland-Palatinate 55131, Germany
  • GSK Investigational Site
    Herne, 44649, Germany
  • GSK Investigational Site
    Lübeck, 23538, Germany
  • GSK Investigational Site
    Mainz, 55131, Germany
  • GSK Investigational Site
    Meerbusch, 40668, Germany
  • GSK Investigational Site
    Athens, 11 527, Greece
  • GSK Investigational Site
    Athens, 12462, Greece
  • GSK Investigational Site
    Athens, 16673, Greece
  • GSK Investigational Site
    Heraklion, 71500, Greece
  • GSK Investigational Site
    Thessaloniki, 54642, Greece
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Ferrara, 44124, Italy
  • GSK Investigational Site
    Milan, 20132, Italy
  • GSK Investigational Site
    Pisa, 56100, Italy
  • GSK Investigational Site
    Reggio Emilia, 42123, Italy
  • GSK Investigational Site
    Rome, 00168, Italy
  • GSK Investigational Site
    Rozzano, 20089, Italy
  • GSK Investigational Site
    Fukuoka, 807-8556, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Osaka, 590-0197, Japan
  • GSK Investigational Site
    Tokyo, 104-8560, Japan
  • GSK Investigational Site
    Cuauhtémoc, Mexico City 06090, Mexico
  • GSK Investigational Site
    DF, 14000, Mexico
  • GSK Investigational Site
    Guadalajara Jalisco, 44950, Mexico
  • GSK Investigational Site
    León, 37000, Mexico
  • GSK Investigational Site
    Mexico City, 06700, Mexico
  • GSK Investigational Site
    Mexico City, 06726, Mexico
  • GSK Investigational Site
    Mérida, 97000, Mexico
  • GSK Investigational Site
    Monterrey Nuevo LeOn, 64000, Mexico
  • GSK Investigational Site
    San Luis Potosí City, 78200, Mexico
  • GSK Investigational Site
    Torreón, 27000, Mexico
  • GSK Investigational Site
    Almada, Setúbal District 2805-267, Portugal
  • GSK Investigational Site
    Lisbon, 1069-166, Portugal
  • GSK Investigational Site
    Porto, 4050-342, Portugal
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Castellon, 12004, Spain

Showing the first 100 of 104 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.

Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's planned 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
May 13, 2024
StartActual
Jun 6, 2024
Primary completionEst.
Jun 29, 2027
CompletionEst.
Jul 30, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 9 sites removed
Show 4 added (2 Brazil, 1 Germany, 1 Portugal)
  • GSK Investigational Site · Belo Horizonte, Brazil
  • GSK Investigational Site · São José do Rio Preto, Brazil
  • GSK Investigational Site · Mainz, Germany
  • GSK Investigational Site · Almada, Portugal
Show 9 removed
  • GSK Investigational Site · Philadelphia, United States
  • GSK Investigational Site · Belo Horizonte, Brazil
  • GSK Investigational Site · São José do Rio Preto, Brazil
  • GSK Investigational Site · Lille, France
  • GSK Investigational Site · Pessac, France
  • GSK Investigational Site · Rennes, France
  • GSK Investigational Site · Kanagawa, Japan
  • GSK Investigational Site · Almada, Portugal
  • GSK Investigational Site · Villajoyosa, Spain
Oct 27, 2026
Study completion
Jul 17, 2029→Jul 30, 2029
Oct 27, 2026
Enrollment
303→302
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    4 sites added, 9 sites removed
    Show 4 added (2 Brazil, 1 Germany, 1 Portugal)
    • GSK Investigational Site · Belo Horizonte, Brazil
    • GSK Investigational Site · São José do Rio Preto, Brazil
    • GSK Investigational Site · Mainz, Germany
    • GSK Investigational Site · Almada, Portugal
    Show 9 removed
    • GSK Investigational Site · Philadelphia, United States
    • GSK Investigational Site · Belo Horizonte, Brazil
    • GSK Investigational Site · São José do Rio Preto, Brazil
    • GSK Investigational Site · Lille, France
    • GSK Investigational Site · Pessac, France
    • GSK Investigational Site · Rennes, France
    • GSK Investigational Site · Kanagawa, Japan
    • GSK Investigational Site · Almada, Portugal
    • GSK Investigational Site · Villajoyosa, Spain
    Study completion Jul 17, 2029→Jul 30, 2029
    Enrollment 303→302
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06411249
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Jun 6, 2024
Primary completion
Jun 29, 2027 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion